Enorama Pharma's CEO resigns, Amy Walker becomes acting CEO
The resignation is for personal reasons. Amy Walker assumes the role of acting CEO with immediate effect.
See the latest news and media coverage for Enorama Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.
Swedish pharmaceutical company developing oral nicotine products
enoramapharma.comLast updated
In short: Enorama Pharma underwent multiple leadership changes, faced severe financial distress after an FDA setback, and divested its gum business.
The resignation is for personal reasons. Amy Walker assumes the role of acting CEO with immediate effect.
The meeting resolved no dividend, carried forward profits, and authorized share issuances.
The purchase price is 100,000 EUR. The deal includes marketing authorizations and patents.
Shareholders are invited to participate on 16 June 2026 in Malmö, with registration by 10 June, and proposals for the board and share issue.
Close Agenda: Rusta, Zalando and definitive KPI. Thursday's highlights with Noel Hermansson The equity in Enorama Pharma, a company active in tobacco-free white snus, is below...
Enorama Pharma AB (publ) ("Enorama Pharma" or "the Company") announces today an organizational change in the board and management group. The board has, in agreement with managing director Daniel Schröder...
Enorama Pharma Inc. filed a lawsuit against the U.S. Food and Drug Administration in federal court in Washington, D.C., alleging the agency unlawfully imposed costly...
The board of directors in Enorama Pharma, active in tobacco-free white snus, has decided to prepare a control balance sheet.
Track Enorama Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Enorama Pharma and other trending companies.